In vitro activity of oxazaphosphorines in childhood acute leukemia : preliminary report by Styczyński, Jan et al.
In vitro activity of oxazaphosphorines in childhood acute
leukemia: Preliminary report
Jan Styczyñski1, , Mariusz Wysocki1, Robert Dêbski1, Walentyna Balwierz2,
Roma Rokicka-Milewska3, Micha³ Matysiak4, Anna Balcerska5, Jerzy Kowalczyk6,
Jacek Wachowiak7, Danuta Soñta-Jakimczyk8 and Alicja Chybicka9
1
Department of Pediatric Hematology and Oncology, Medical University, Bydgoszcz, Poland;
2
Department of Pediatric Hematology, Collegium Medicum Jagiellonian University, Kraków,
Poland;
3
Department of Pediatric Hematology and Oncology,
4
Department of Pediatric
Pulmonology, Alergology and Hematology, Medical University, Warszawa, Poland;
5Department
of Pediatric Hematology, Oncology and Endocrinology, Medical University, Gdañsk, Poland;
6
Department of Pediatric Hematology and Oncology, Medical University, Lublin, Poland;
7Department of Pediatric Hematology and Oncology, Medical University, Poznañ, Poland;
8
Department of Pediatric Hematology and Chemotherapy, Silesian Medical University, Zabrze,
Poland;
9
Department of Pediatric Hematology and Oncology, Medical University, Wroc³aw,
Poland
Received: 10 September, 2001; revised: 03 January, 2002; accepted: 21 February, 2002
Key words: glufosfamide, leukemia, ALL, sensitivity, resistance
Glufosfamide (-D-glucosyl-ifosfamide mustard) is a new agent for cancer chemo-
therapy. Its pharmacology is similar to commonly used oxazaphosphorines, but it
does not require activation by hepatic cytochrome P-450 and preclinically demon-
strates lower nephrotoxicity and myelosuppression than ifosfamide. The aim of the
study was a comparison of the drug resistance profiles of glufosfamide and other
oxazaphosphorines in childhood acute leukemias. Leukemic cells, taken from chil-
dren with ALL on diagnosis (n = 41), ALL on relapse (n = 12) and AML on diagnosis (n
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= 13) were analyzed by means of the MTT assay. The following drugs were tested:
glufosfamide (GLU), 4-HOO-ifosfamide (IFO), 4-HOO-cyclophosphamide (CYC) and
mafosfamide cyclohexylamine salt (MAF). In the group of initial ALL samples median
cytotoxicity values for GLU, IFO, CYC and MAF were 15.5, 33.8, 15.7 and 7.8 M, re-
spectively. In comparison with initial ALL samples, the relative resistance for GLU
and IFO in relapsed ALL samples was 1.9 (p = 0.049) and 1.3 (ns), and in initial AML
samples 31 (p < 0.001) and 5 (p = 0.001), respectively. All oxazaphosphorines pre-
sented highly significant cross-resistance. Glufosfamide presented high activity
against lymphoblasts both on diagnosis and on relapse.
Oxazaphosphorines are a class of alkylating
agents with a high experimental and clinical
antitumor activity. Cyclophosphamide and
ifosfamide are prodrugs, which need meta-
bolic activation by cytochrome P-450 enzymes
of the liver to generate the cytotoxic species
[1]. The goal of search for analogues has been
to synthesize “activated” oxazaphosphorines,
which hydrolyze spontaneously to form pri-
mary 4-hydroxy-metabolites. However, one of
those agents, mafosfamide, was difficult to de-
velop clinically because of severe pain at the
injection site, which probably resulted from
acrolein generated during spontaneous degra-
dation of the molecule during infusion [2, 3].
Glufosfamide (-D-glucosyl-isophosphoramide
mustard) is a new agent for cancer chemother-
apy with pharmacology similar to commonly
used oxazaphosphorines, which does not re-
quire activation by cytochrome P-450 [4, 5].
Glufosfamide preclinically demonstrated less
nephrotoxicity and myelosuppression than
ifosfamide [6]. The cytotoxic activity of
glufosfamide is dependent on DNA alkylating
properties [4]. A more detailed analysis of the
mechanism of glufosfamide action showed
that the drug impaired protein and DNA syn-
thesis, and triggered the activation of
poly(ADP-ribose) polymerase (PARP), an en-
zyme specifically sensing DNA strand-breaks
[7]. As cyclophosphamide and ifosfamide are
widely used in the therapy of acute
lymphoblastic leukemia (ALL), both initial
(iALL) and at relapse (rALL), the objective of
the study was an analysis of the drug resis-
tance profile of glufosfamide in comparison
with other oxazaphosphorines in childhood
acute leukemia.
MATERIALS AND METHODS
Leukemic cells were taken from 24 girls and
42 boys, aged 0.4–18 yrs (median 7.0 yrs) with
diagnoses: initial ALL (iALL, n = 41), ALL on
relapse (rALL, n = 12) and initial acute
myeloblastic leukemia (iAML, n = 13). Drug
resistance was analyzed by means of the
4-days MTT assay [8]. Only samples with at
least 80% leukemic cells in the isolate suspen-
sion were analyzed. The following drugs be-
longing to the group of oxazaphosphorines
were tested: glufosfamide (GLU), 4-HOO-ifos-
famide (IFO), 4-HOO-cyclophosphamide
(CYC) and mafosfamide cyclohexylamine salt
(MAF) (all provided kindly by ASTA Medica,
Frankfurt, Germany) (Fig. 1, Table 1). Drug
concentration lethal to 50% of tested cells
(LC50) was used as a measure of cytotoxicity.
Differences between groups were compared
with Mann-Whitney U test. Correlation be-
tween cytotoxicity of drugs was determined
by Spearman’s rho coefficient. The study was
approved by the Local Ethics Committee of
Medical University (Bydgoszcz, Poland).
RESULTS AND DISCUSSION
In the group of initial ALL samples, equiva-
lent LC50 values for GLU, IFO, CYC and MAF
were 15.5, 33.8, 15.7 and 7.8 M, respectively.
The relative resistance in relapsed ALL sam-
ples, in comparison with initial ALL samples,
was 1.9 (p = 0.049) for GLU and 1.3 (p > 0.05)
for IFO. The group of initial AML samples was
31-fold more resistant (p < 0.001) to GLU and
5-fold (p = 0.001) to IFO than iALL samples
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(Table 2). All oxazaphosphorines showed
highly significant cross-resistance within each
pair of drugs (Table 3).
Glufosfamide shows similarity to ifosfamide
in its cytotoxic effects, due to the formation of
ifosfamide mustard, a metabolite of both com-
pounds [7]. Glufosfamide is chemically stable,
but can be split by intracellular glycolytic en-
zymes [5]. Its selectivity for tumor cells is
probably due to active transport by glucose
carriers. Yet the toxicity of glufosfamide for
white blood cells, colony forming units and
spleen colony forming units is considerably
lower compared with ifosfamide. Side effects
in the urinary tract are avoided, since no
acrolein is formed. Free acrolein is responsi-
ble for the severe side effects in the urinary
tract that are typical for this class of alky-
lating agents [4]. Another important differ-
ence between these drugs is that it was possi-
ble to provoke resistance of SKOV3 cells to
continuous treatment with ifosfamide but not
to glufosfamide [7].
We tested if glufosfamide might be able to
circumvent resistance to cyclophosphamide
and ifosfamide in samples of childhood acute
leukemias. Glufosfamide presented a favour-
able cytotoxicity profile in ALL cells both on
diagnosis and at relapse. However, cross-re-
sistance with other oxazaphosphorines and
other tested drugs was observed. Should the
toxicity profile be taken into account, this
drug might be considered useful in future clin-
ical practice. Since cyclophosphamide is often
used in the conditioning regimen before
allogenic or autologous hemopoietic stem cell
transplantation, and mafosfamide is used for
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Figure 1. Chemical structure of oxazaphospho-
rines.
Table 1. Concentration ranges of the drugs tested
Molecular mass
[g/mol]
Concentration range
[M]
Glufosfamide 383.16 0.50–522.0
4-HOO-ifosfamide 293.10 0.33–341.2
4-HOO-cyclophosphamide 293.10 0.33–341.2
Mafosfamide 500.45 0.19–200.0
bone marrow purging [9], it seems that with
its cytotoxicity profile glufosfamide might be
also used in transplantation procedures in
acute lymphoblastic leukemia. On the other
hand, very weak activity of glufosfamide was
observed against AML cells, typical also for
other drugs belonging to this group. Con-
cluding, the in vitro activity of glufosfamide is
comparable to other oxazaphosphorines.
Glufosfamide shows high activity against
lymphoblasts both on diagnosis and on re-
lapse, but because of high cross-resistance it
cannot circumvent resistance to other
oxazaphosphorines.
Authors thank Beata Ko³odziej for technical
assistance.
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Table 2. Median cytotoxicity (LC50) and relative resistance (RR) values
Median LC50 [g/ml] Relative resistance, p-value
iALL rALL iAML RR(rALL/iALL)* RR(iAML/iALL)**
Glufosfamide 5.95 11.41 189.7 1.9; p = 0.049 31; p = 0.000
4-HOO-ifosfamide 9.92 13.69 55 1.3; p > 0.050 5.0; p = 0.001
4-HOO-cyclophosphamide 4.6 7.82 40.02 1.7; p > 0.050 8.7; p = 0.015
Mafosfamide 3.9 23.4 46.8 6.0; p = 0.001 12; p = 0.000
RR, relative resistance in comparison with iALL; (*) RR is the median LC50 for rALL divided by the median LC50 for iALL; (**)
RR is the median LC50 for iAML divided by the median LC50 for iALL; RR > 1 indicates that for the given drug, rALL (iAML) is
more resistant than iALL; p, Mann-Whitney U test.
Table 3. Correlation matrix of cross-resistant cytotoxicity (expressed by LC50 values)
GLU IFO CYC MAF
GLU 0.619 0.749 0.777
< 0.001 < 0.000 < 0.001
IFO 0.619 0.880 0.846
< 0.001 < 0.001 < 0.001
CYC 0.749 0.880 0.906
< 0.001 < 0.001 < 0.001
MAF 0.777 0.846 0.906
< 0.001 < 0.001 < 0.001
Upper number in each field is the value of Spearman’s rho coefficient of correlation of LC50 values for a pair of drugs, lower num-
ber – p-value of this coefficient. GLU, glufosfamide; IFO, 4-HOO-ifosfamide; CYC, 4-HOO-cyclophosphamide; MAF, mafosfamide
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